Private Capital's Strategic Moves: Significant Reduction in Everi Holdings Inc.
Warning! GuruFocus has detected 2 Warning Sign with QNST.
Private Capital (Trades, Portfolio) recently submitted its 13F filing for the first quarter of 2025, offering a glimpse into its strategic investment decisions during this period. Founded by Bruce Sherman in 1986, Private Capital (Trades, Portfolio) Management has a rich history in value investing. Sherman, a Certified Public Accountant, initially worked with the Collier Family, managing their investments. After his retirement in 2009, Gregg J. Powers took over as CEO. Powers, who began his career as a healthcare analyst at Raymond James Financial, joined Private Capital (Trades, Portfolio)'s investment research team in 1988. The firm adheres to a value investing philosophy, focusing on acquiring stocks at 40% below their intrinsic value, managing downside risk, and employing patience to achieve long-term portfolio gains.
Private Capital (Trades, Portfolio) added a total of 15 stocks, among them:
The most significant addition was ACNB Corp (NASDAQ:ACNB), with 271,596 shares, accounting for 1.22% of the portfolio and a total value of $11.15 million.
The second largest addition to the portfolio was Astronics Corp (NASDAQ:ATRO), consisting of 402,958 shares, representing approximately 1.06% of the portfolio, with a total value of $9.72 million.
The third largest addition was Pioneer Bancorp Inc (NASDAQ:PBFS), with 259,904 shares, accounting for 0.33% of the portfolio and a total value of $3.04 million.
Private Capital (Trades, Portfolio) also increased stakes in a total of 61 stocks, among them:
The most notable increase was International Workplace Group PLC (IWGFF), with an additional 6,537,814 shares, bringing the total to 7,271,825 shares. This adjustment represents a significant 890.7% increase in share count, a 1.72% impact on the current portfolio, with a total value of $17.41 million.
The second largest increase was BGC Group Inc (NASDAQ:BGC), with an additional 836,470 shares, bringing the total to 3,998,857. This adjustment represents a significant 26.45% increase in share count, with a total value of $36.59 million.
Private Capital (Trades, Portfolio) completely exited 11 holdings in the first quarter of 2025, as detailed below:
Visteon Corp (NASDAQ:VC): Private Capital (Trades, Portfolio) sold all 89,857 shares, resulting in a -0.84% impact on the portfolio.
Shore Bancshares Inc (NASDAQ:SHBI): Private Capital (Trades, Portfolio) liquidated all 239,255 shares, causing a -0.4% impact on the portfolio.
Private Capital (Trades, Portfolio) also reduced positions in 35 stocks. The most significant changes include:
Reduced Everi Holdings Inc (NYSE:EVRI) by 1,351,379 shares, resulting in a -79.54% decrease in shares and a -1.92% impact on the portfolio. The stock traded at an average price of $13.65 during the quarter and has returned 2.40% over the past 3 months and 4.15% year-to-date.
Reduced Jefferies Financial Group Inc (NYSE:JEF) by 117,561 shares, resulting in a -22.78% reduction in shares and a -0.97% impact on the portfolio. The stock traded at an average price of $67.88 during the quarter and has returned -25.28% over the past 3 months and -31.49% year-to-date.
At the first quarter of 2025, Private Capital (Trades, Portfolio)'s portfolio included 149 stocks. The top holdings included 7.96% in QuinStreet Inc (NASDAQ:QNST), 5.59% in Lantheus Holdings Inc (NASDAQ:LNTH), 5.5% in Harrow Inc (NASDAQ:HROW), 5.15% in Barrett Business Services Inc (NASDAQ:BBSI), and 4.05% in PowerFleet Inc (NASDAQ:AIOT).
The holdings are mainly concentrated in 11 industries: Financial Services, Industrials, Communication Services, Healthcare, Technology, Consumer Cyclical, Basic Materials, Real Estate, Energy, Consumer Defensive, and Utilities.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Citi Reaffirms Buy on Broadcom (AVGO) Amid Surging AI Revenue
Broadcom Inc. (NASDAQ:AVGO) is one of the 10 best tech stocks to buy according to billionaires right now. On June 9, a Citi analyst raised his price target on Broadcom from $276 to $285 while maintaining a Buy rating. This revision follows Broadcom's second-quarter results, which showed continued strength in AI-related revenue, although overall performance was mixed, as per the analyst, due to some pressure on margins. Broadcom continues to benefit from growing demand in the artificial intelligence space, which remains a key driver of topline performance. The company reported Q2 FY 2025 revenue of $15.0 billion, up 20% year-over-year supported by strong AI semiconductor sales and contributions from VMware. Adjusted EBITDA rose 35% year-over-year to $10.0 billion, implying an EBITDA margin of 67%. A worker assembling the inner circuitry of a semiconductor product. AI-related revenue reached $4.4 billion in Q2, growing 46% year-over-year, driven primarily by demand for AI networking solutions. Management expects this momentum to carry into Q3, with AI semiconductor revenue projected to reach $5.1 billion. This growth is supported by continued investment by hyperscale customers. Looking ahead, Broadcom guided for Q3 FY25 revenue of approximately $15.8 billion and an adjusted EBITDA margin of at least 66% of revenue, which is slightly below versus Q2. However, the company's margin outlook raised some concerns. According to the analyst, an increased contribution of semiconductor sales in total sales has put pressure on profitability. In response, management has adjusted its guidance, which indicates a slightly lower margin in the near term. Broadcom Inc. (NASDAQ:AVGO) is a global technology company that designs, develops, and supplies a wide range of semiconductor and infrastructure software solutions. The company's products play a crucial role in enterprise and data center networking, broadband access, storage systems, smartphones, and wireless communications. Broadcom's extensive portfolio includes solutions for data center networking, storage, and security, making it a key player in the data center ecosystem. While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, analysts from Raymond James resumed coverage of Disc Medicine, Inc. (NASDAQ:IRON) with a strong Buy rating and a price target of $89. The resumed coverage comes as the company released its research note on Biotech names. The firm highlighted a favorable risk/reward profile in the biotech sector. It noted that while companies with a high probability of success for lead assets inspire higher conviction, investments in less de-risked assets like Disc Medicine, Inc. (NASDAQ:IRON) could yield the most outsized returns. The firm sees more than $1 billion potential for the company's drug bitopertin, with an expected market penetration of about 30%-35%, owing to its disease-modifying agent capabilities X-linked protoporphyria. A scientist in a laboratory setting examining a sample of blood with a microscope. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on discovering therapies for serious hematologic diseases. Its pipeline includes drug candidates like bitopertin for erythropoietic porphyrias and Diamond-Blackfan Anemia, DISC-0974 for anemia related to myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other blood disorders. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
2 hours ago
- Yahoo
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
